The global pollen allergy market is currently valued at US$ 5850.8 Million in 2023 and is anticipated to expand at a CAGR of 4.2%. Owing to the technological advances in healthcare the market is likely to propel to US$ 8828.6 Million by 2033.
“The rising prevalence of allergic disorders and their burden across the globe are likely to drive the growth of the pollen allergy market in the forecast period.”
| Report Attribute | Details |
|---|---|
| Expected Market Value (2023) | US$ 5850.8 Million |
| Projected Forecast Value (2033) | US$ 8828.6 Million |
| Global Growth Rate (2023 to 2033) | 4.2% CAGR |
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
The pollen allergy market is expected to gain market growth in the forecast period of 2023 to 2033. Latest market analysis by FMI the market is to grow at a CAGR of 4.2% in the above-mentioned forecast period.
Pollens are referred to as mostly consist of tiny particles released by grasses, trees, and plants during their reproductive cycle. These pollen particles can easily gasp by animals and humans which can cause inflammation and irritation to some individuals and this allergy can lead to fever and rhinitis.
Patients with pollen allergy need to be aware of the changes that can occur in their area to help them adapt to changes in the pattern and presentation of disease that may result from climate change. The global pollen allergy market rose at a CAGR of 3.8% from 2018 to 2022.
The rising Prevalence of Allergy and Changing Lifestyle Leading to Decreased Immune Resistance drive the Pollen Allergy Market
The rise in the number of patients suffering from pollen-based allergies and more precisely hay fever drives the growth of the market. Moreover, the growing number of patients especially children is another contributor to escalating the global pollen allergy market. Rapid urbanization in the advancing countries is the major factor that boosts the growth of the pollen allergies market in the forecast period.
Allergy is considered a risk factor for asthma, chronic inflammatory conditions and reduce quality of life. Because of these factors, there is a high need for the treatment of allergies. The global pollen allergy market is expected to show tremendous growth due to increased Pharmaceutical Research and Development spending and biotechnology investment.
The increase in greenhouse gas can result in pollen-induced reparative disease which is further estimated to cushion the growth of the pollen allergies market. Increasing environmental pollution will further provide opportunities for the growth of the pollen allergies market in the coming years.
Increase in Healthcare Spending and Government Initiatives to Drive the Market Growth
Over the past few decades, it has been noted that global per capita healthcare spending has increased considerably owing to the increasing rate of awareness regarding the availability of myriad treatments and diagnostic methods for treating various diseases.
Increasing healthcare spending is likely to result in increasing demand for better quality and rapid diagnostic methods, and in turn, create high growth opportunities for players operating in the treatment of pollen allergies market.
Respiratory disease places a huge burden on society in terms of disability and premature mortality, and also in direct health service costs, drugs prescribed, and the indirect costs related to lost production. Pollen allergy is frequently accompanied by allergic asthma treatment. This condition is also impacting the global pollen allergy market.
In order to increase awareness about allergic rhinitis, several government organizations have started awareness programs. For instance, Allergy UK is the operational name of the British Allergy Foundation that observes allergy awareness week from April 25 to May 1.
Principal Consultant
Increased Awareness Regarding Allergy Immunotherapy to Hamper the Market Growth
Despite a positive growth trajectory, the global pollen allergy market is facing various challenges that are likely to pose a threat to its growth during the forecast period.
The lack of a permanent cure for grass pollen allergy disease and home-based diagnosis are a few restraints to the growth of the global pollen allergy market. The rise in the preference towards the utilization of biosimilars is further projected to impede the growth of the pollen allergies market in the forecast period.
However, the decrease in the awareness of allergy immunotherapy (AIT) amongst patients might further challenge the growth of the pollen allergies market in the near future
“Increasing Rate of Allergic Diseases in the US to Propel the Market Growth”
The US is estimated to account for over 40% of the North American market in 2023. North America has dominated the global pollen allergy market due to the increased incidence rate of allergies and awareness of therapy.
A study conducted by the American College of Allergy, Asthma & Immunology in 2010 reported that about 16.9 million adults and 6.7 million children were diagnosed with hay fever and its prevalence is increasing by approximately 30% in adults and 40% in children.
The United States Food and Drug Administration 2014 estimated around 30 million people in the United States and 500 million globally suffer from one or other form of hay fever symptoms.
Moreover, the increasing focus on Research and Development to develop novel products to cater to high unmet medical needs is highly impacting the market’s growth.
For instance, GlaxoSmithKline plc announced that the US Food and Drug Administration (FDA) has approved Flonase® Allergy Relief (fluticasone propionate 50 mcg spray), containing the No. 1 prescribed allergy treatment ingredient1, as an over-the-counter (OTC) treatment for temporary relief of the symptoms of hay fever or upper respiratory allergies.2
Rising Prevalence of Respiratory Allergic Disorders Driving Growth in the Europe Market
The Europe pollen allergy market is expected to rise at a CAGR of 4.0% from 2023 to 2033. Europe is expected to have the second-largest market for global pollen allergy market. Increasing awareness among people about diseases is also a major factor that may boost the growth of the market in this region.
Europe dominates the pollen allergies market due to the rise in the prevalence of respiratory allergic disorders. Europe is the fastest-growing market in pollen allergy due to increasing healthcare funding by the government. Moreover, an increase in the need for therapeutics is further anticipated to propel the growth pollen allergies market in the region in the coming years.
The Charity Allergy UK estimated that about 18 million people were found to be affected with grass pollen allergy which is more common among children and teenagers. Symptoms of pollen include frequent sneezing, running or blocked nose, and itchy eyes, and throat. In some instances, it can also lead to loss of senses to smell, facial pain, sweating, and severe headache. People suffering from asthma face even worse symptoms which include tight chest, shortness of breath, coughing, and wheezing.
Advancement in Healthcare to Propel the Market Growth
Asia Pacific is anticipated to expand at the fastest CAGR of 3.8% during the forecast period. Asia Pacific emerged as the fastest-growing region in the pollen allergy market owing to the presence of unmet healthcare infrastructure needs and the increasing prevalence of allergic diseases.
Furthermore, favorable government initiatives in regions like Japan and Australia pertaining to drug price adjustment and the development of novel drugs for the treatment of pollen allergy are expected to provide manufacturers with lucrative future growth opportunities.
| Country | CAGR |
|---|---|
| The UK | 4.0% |
| India | 3.7% |
| South Korea | 3.6% |
| China | 3.8% |
| The US | 4.2% |
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
Corticosteroids Segment Remains Dominant Among Other Types
Antihistamines, Decongestants, Corticosteroids, Mast Cell Stabilizers, Leukotriene Inhibitors, Nasal Anticholinergics, Immunomodulators, Auto injectable Epinephrine, and Immunotherapy are the key segments analyzed in the scope of the study.
Corticosteroids dominated the pollen allergy market in 2023 with a revenue share of 35.5%. Corticosteroids are mostly used as the first line of treatment and are also expected to contribute towards the aforementioned conclusion.
Whereas, calcineurin inhibitors are expected to grow at the fastest CAGR during the forecast period owing to their high response rate and the presence of a strong pipeline of calcineurin inhibitors and semi-synthetic analogs of these inhibitors.
Inhaled Allergen SignificantlyDominated the Market
Based on allergen type, the market is categorized into food, inhaled, drug, and others. Inhaled allergens led the global pollen allergy market in 2023 due to increased incidences of respiratory allergies across the globe. The segment is projected to expand further at the fastest CAGR owing to the high demand for allergy testing and the introduction of specific allergens for the detection of pollen allergy.
The drug allergies segment is also expected to register a strong CAGR of 3.8% from 2023 to 2033. Food allergies were the second-largest segment, in terms of revenue share, and are projected to continue the trend throughout the forecast years. Children are more susceptible to these types of allergic diseases. According to the estimates published by the US National Institute of Health (NIH), the prevalence of food allergies among children is double that of adults.
With technological innovations happening at a rapid pace, and companies looking for ways to increase customer engagement, start-ups are taking all possible steps to establish a name for themselves in the pollen allergy market.
Some of the start-ups in the pollen allergy market include-
The professional survey study carefully analyses the operations and overview of the corporate structures and functioning of the leading and major manufacturers and players functional within the global pollen allergy market. It assesses its product offerings, financial outlook, sales, revenue, and growth over the forecast period.
Some of the leading manufacturers and players assessed in the global pollen allergy market are bioMerieux SA, HOB Biotech Group Corp Ltd, Alcon, HYCOR Biomedical, Inc, Immunomic Therapeutics, Quest Diagnostics Incorporated, Omega Diagnostics Group PLC, Siemens Healthcare Private Limited, Stallergenes Greer, Lincoln Diagnostics, Inc., and others
Manufacturers and players functional in the pollen allergy market are adopting various corporate growth strategies such as new product launches, mergers and acquisitions, and geographical expansion, among others.
| Report Attribute | Details |
|---|---|
| Growth Rate | CAGR from 2023 to 2033 |
| Expected Market Value (2023) | US$ 5850.8 Million |
| ProjectedForecast Value (2033) | US$ 8828.6 Million |
| Base Year for Estimation | 2022 |
| Historical Data | 2018 to 2022 |
| Forecast Period | 2023 to 2033 |
| Quantitative Units | Revenue in USD Million & CAGR from 2023 to 2033 |
| Report Coverage | Revenue Forecast, Volume Forecast, Company Ranking, Competitive L&scape, Growth Factors, Trends & Pricing Analysis |
| Segments Covered |
|
| Regions Covered |
|
| Key Countries Profiled |
|
| Key Companies Profiled |
|
| Customization | Available Upon Request |
The global pollen allergy market is likely to reach a valuation of US$ 5850.8 million by the end of 2023.
bioMerieux SA, HOB Biotech Group Corp Ltd, Alcon, HYCOR Biomedical, Inc, and Immunomic Therapeutics are some of the key players in the global pollen allergy market.
Sales of the pollen allergy market are likely to expand at 4.2% CAGR through 2033.
The US, Canada, Japan, China, & Germany are expected to drive most of the demand for the pollen allergy market.
By the end of 2033, the global market for pollen allergy market is predicted to reach a valuation of US$ 8828.6 Million
1. Executive Summary | Pollen Allergy Market
1.1. Global Market Outlook
1.2. Demand-side Trends
1.3. Supply-side Trends
1.4. Technology Roadmap Analysis
1.5. Analysis and Recommendations
2. Market Overview
2.1. Market Coverage / Taxonomy
2.2. Market Definition / Scope / Limitations
3. Market Background
3.1. Market Dynamics
3.1.1. Drivers
3.1.2. Restraints
3.1.3. Opportunity
3.1.4. Trends
3.2. Scenario Forecast
3.2.1. Demand in Optimistic Scenario
3.2.2. Demand in Likely Scenario
3.2.3. Demand in Conservative Scenario
3.3. Opportunity Map Analysis
3.4. Investment Feasibility Matrix
3.5. PESTLE and Porter’s Analysis
3.6. Regulatory Landscape
3.6.1. By Key Regions
3.6.2. By Key Countries
3.7. Regional Parent Market Outlook
4. Global Market Analysis 2018 to 2022 and Forecast, 2023 to 2033
4.1. Historical Market Size Value (US$ Million) Analysis, 2018 to 2022
4.2. Current and Future Market Size Value (US$ Million) Projections, 2023 to 2033
4.2.1. Y-o-Y Growth Trend Analysis
4.2.2. Absolute $ Opportunity Analysis
5. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Product
5.1. Introduction / Key Findings
5.2. Historical Market Size Value (US$ Million) Analysis By Product, 2018 to 2022
5.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Product, 2023 to 2033
5.3.1. Instruments
5.3.2. Consumables
5.3.3. Services
5.4. Y-o-Y Growth Trend Analysis By Product, 2018 to 2022
5.5. Absolute $ Opportunity Analysis By Product, 2023 to 2033
6. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Allergen Type
6.1. Introduction / Key Findings
6.2. Historical Market Size Value (US$ Million) Analysis By Allergen Type, 2018 to 2022
6.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Allergen Type, 2023 to 2033
6.3.1. Food
6.3.2. Inhaled
6.3.3. Drug
6.3.4. Others
6.4. Y-o-Y Growth Trend Analysis By Allergen Type, 2018 to 2022
6.5. Absolute $ Opportunity Analysis By Allergen Type, 2023 to 2033
7. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Therapeutics Drug Class
7.1. Introduction / Key Findings
7.2. Historical Market Size Value (US$ Million) Analysis By Therapeutics Drug Class, 2018 to 2022
7.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Therapeutics Drug Class, 2023 to 2033
7.3.1. Antihistamines
7.3.2. Decongestants
7.3.3. Corticosteroids
7.3.4. Mast Cell Stabilizers
7.3.5. Leukotriene Inhibitors
7.3.6. Nasal Anticholinergics
7.3.7. Immunomodulators
7.3.8. Auto injectable Epinephrine
7.3.9. Immunotherapy
7.4. Y-o-Y Growth Trend Analysis By Therapeutics Drug Class, 2018 to 2022
7.5. Absolute $ Opportunity Analysis By Therapeutics Drug Class, 2023 to 2033
8. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By End User
8.1. Introduction / Key Findings
8.2. Historical Market Size Value (US$ Million) Analysis By End User, 2018 to 2022
8.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By End User, 2023 to 2033
8.3.1. Diagnostic Laboratories
8.3.2. Hospitals
8.3.3. Academic Research Institutes
8.4. Y-o-Y Growth Trend Analysis By End User, 2018 to 2022
8.5. Absolute $ Opportunity Analysis By End User, 2023 to 2033
9. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Region
9.1. Introduction
9.2. Historical Market Size Value (US$ Million) Analysis By Region, 2018 to 2022
9.3. Current Market Size Value (US$ Million) Analysis and Forecast By Region, 2023 to 2033
9.3.1. North America
9.3.2. Latin America
9.3.3. Europe
9.3.4. South Asia
9.3.5. East Asia
9.3.6. Oceania
9.3.7. Middle East & Africa (MEA)
9.4. Market Attractiveness Analysis By Region
10. North America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
10.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
10.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
10.2.1. By Country
10.2.1.1. The US
10.2.1.2. Canada
10.2.2. By Product
10.2.3. By Allergen Type
10.2.4. By Therapeutics Drug Class
10.2.5. By End User
10.3. Market Attractiveness Analysis
10.3.1. By Country
10.3.2. By Product
10.3.3. By Allergen Type
10.3.4. By Therapeutics Drug Class
10.3.5. By End User
10.4. Key Takeaways
11. Latin America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
11.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
11.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
11.2.1. By Country
11.2.1.1. Brazil
11.2.1.2. Mexico
11.2.1.3. Rest of Latin America
11.2.2. By Product
11.2.3. By Allergen Type
11.2.4. By Therapeutics Drug Class
11.2.5. By End User
11.3. Market Attractiveness Analysis
11.3.1. By Country
11.3.2. By Product
11.3.3. By Allergen Type
11.3.4. By Therapeutics Drug Class
11.3.5. By End User
11.4. Key Takeaways
12. Europe Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
12.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
12.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
12.2.1. By Country
12.2.1.1. Germany
12.2.1.2. The UK
12.2.1.3. France
12.2.1.4. Spain
12.2.1.5. Italy
12.2.1.6. Rest of Europe
12.2.2. By Product
12.2.3. By Allergen Type
12.2.4. By Therapeutics Drug Class
12.2.5. By End User
12.3. Market Attractiveness Analysis
12.3.1. By Country
12.3.2. By Product
12.3.3. By Allergen Type
12.3.4. By Therapeutics Drug Class
12.3.5. By End User
12.4. Key Takeaways
13. South Asia Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
13.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
13.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
13.2.1. By Country
13.2.1.1. India
13.2.1.2. Malaysia
13.2.1.3. Singapore
13.2.1.4. Thailand
13.2.1.5. Rest of South Asia
13.2.2. By Product
13.2.3. By Allergen Type
13.2.4. By Therapeutics Drug Class
13.2.5. By End User
13.3. Market Attractiveness Analysis
13.3.1. By Country
13.3.2. By Product
13.3.3. By Allergen Type
13.3.4. By Therapeutics Drug Class
13.3.5. By End User
13.4. Key Takeaways
14. East Asia Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
14.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
14.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
14.2.1. By Country
14.2.1.1. China
14.2.1.2. Japan
14.2.1.3. South Korea
14.2.2. By Product
14.2.3. By Allergen Type
14.2.4. By Therapeutics Drug Class
14.2.5. By End User
14.3. Market Attractiveness Analysis
14.3.1. By Country
14.3.2. By Product
14.3.3. By Allergen Type
14.3.4. By Therapeutics Drug Class
14.3.5. By End User
14.4. Key Takeaways
15. Oceania Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
15.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
15.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
15.2.1. By Country
15.2.1.1. Australia
15.2.1.2. New Zealand
15.2.2. By Product
15.2.3. By Allergen Type
15.2.4. By Therapeutics Drug Class
15.2.5. By End User
15.3. Market Attractiveness Analysis
15.3.1. By Country
15.3.2. By Product
15.3.3. By Allergen Type
15.3.4. By Therapeutics Drug Class
15.3.5. By End User
15.4. Key Takeaways
16. MEA Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
16.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
16.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
16.2.1. By Country
16.2.1.1. GCC Countries
16.2.1.2. South Africa
16.2.1.3. Israel
16.2.1.4. Rest of MEA
16.2.2. By Product
16.2.3. By Allergen Type
16.2.4. By Therapeutics Drug Class
16.2.5. By End User
16.3. Market Attractiveness Analysis
16.3.1. By Country
16.3.2. By Product
16.3.3. By Allergen Type
16.3.4. By Therapeutics Drug Class
16.3.5. By End User
16.4. Key Takeaways
17. Key Countries Market Analysis
17.1. The US.
17.1.1. Pricing Analysis
17.1.2. Market Share Analysis, 2022
17.1.2.1. By Product
17.1.2.2. By Allergen Type
17.1.2.3. By Therapeutics Drug Class
17.1.2.4. By End User
17.2. Canada
17.2.1. Pricing Analysis
17.2.2. Market Share Analysis, 2022
17.2.2.1. By Product
17.2.2.2. By Allergen Type
17.2.2.3. By Therapeutics Drug Class
17.2.2.4. By End User
17.3. Brazil
17.3.1. Pricing Analysis
17.3.2. Market Share Analysis, 2022
17.3.2.1. By Product
17.3.2.2. By Allergen Type
17.3.2.3. By Therapeutics Drug Class
17.3.2.4. By End User
17.4. Mexico
17.4.1. Pricing Analysis
17.4.2. Market Share Analysis, 2022
17.4.2.1. By Product
17.4.2.2. By Allergen Type
17.4.2.3. By Therapeutics Drug Class
17.4.2.4. By End User
17.5. Germany
17.5.1. Pricing Analysis
17.5.2. Market Share Analysis, 2022
17.5.2.1. By Product
17.5.2.2. By Allergen Type
17.5.2.3. By Therapeutics Drug Class
17.5.2.4. By End User
17.6. The UK
17.6.1. Pricing Analysis
17.6.2. Market Share Analysis, 2022
17.6.2.1. By Product
17.6.2.2. By Allergen Type
17.6.2.3. By Therapeutics Drug Class
17.6.2.4. By End User
17.7. France
17.7.1. Pricing Analysis
17.7.2. Market Share Analysis, 2022
17.7.2.1. By Product
17.7.2.2. By Allergen Type
17.7.2.3. By Therapeutics Drug Class
17.7.2.4. By End User
17.8. Spain
17.8.1. Pricing Analysis
17.8.2. Market Share Analysis, 2022
17.8.2.1. By Product
17.8.2.2. By Allergen Type
17.8.2.3. By Therapeutics Drug Class
17.8.2.4. By End User
17.9. Italy
17.9.1. Pricing Analysis
17.9.2. Market Share Analysis, 2022
17.9.2.1. By Product
17.9.2.2. By Allergen Type
17.9.2.3. By Therapeutics Drug Class
17.9.2.4. By End User
17.10. India
17.10.1. Pricing Analysis
17.10.2. Market Share Analysis, 2022
17.10.2.1. By Product
17.10.2.2. By Allergen Type
17.10.2.3. By Therapeutics Drug Class
17.10.2.4. By End User
17.11. Malaysia
17.11.1. Pricing Analysis
17.11.2. Market Share Analysis, 2022
17.11.2.1. By Product
17.11.2.2. By Allergen Type
17.11.2.3. By Therapeutics Drug Class
17.11.2.4. By End User
17.12. Singapore
17.12.1. Pricing Analysis
17.12.2. Market Share Analysis, 2022
17.12.2.1. By Product
17.12.2.2. By Allergen Type
17.12.2.3. By Therapeutics Drug Class
17.12.2.4. By End User
17.13. Thailand
17.13.1. Pricing Analysis
17.13.2. Market Share Analysis, 2022
17.13.2.1. By Product
17.13.2.2. By Allergen Type
17.13.2.3. By Therapeutics Drug Class
17.13.2.4. By End User
17.14. China
17.14.1. Pricing Analysis
17.14.2. Market Share Analysis, 2022
17.14.2.1. By Product
17.14.2.2. By Allergen Type
17.14.2.3. By Therapeutics Drug Class
17.14.2.4. By End User
17.15. Japan
17.15.1. Pricing Analysis
17.15.2. Market Share Analysis, 2022
17.15.2.1. By Product
17.15.2.2. By Allergen Type
17.15.2.3. By Therapeutics Drug Class
17.15.2.4. By End User
17.16. South Korea
17.16.1. Pricing Analysis
17.16.2. Market Share Analysis, 2022
17.16.2.1. By Product
17.16.2.2. By Allergen Type
17.16.2.3. By Therapeutics Drug Class
17.16.2.4. By End User
17.17. Australia
17.17.1. Pricing Analysis
17.17.2. Market Share Analysis, 2022
17.17.2.1. By Product
17.17.2.2. By Allergen Type
17.17.2.3. By Therapeutics Drug Class
17.17.2.4. By End User
17.18. New Zealand
17.18.1. Pricing Analysis
17.18.2. Market Share Analysis, 2022
17.18.2.1. By Product
17.18.2.2. By Allergen Type
17.18.2.3. By Therapeutics Drug Class
17.18.2.4. By End User
17.19. GCC Countries
17.19.1. Pricing Analysis
17.19.2. Market Share Analysis, 2022
17.19.2.1. By Product
17.19.2.2. By Allergen Type
17.19.2.3. By Therapeutics Drug Class
17.19.2.4. By End User
17.20. South Africa
17.20.1. Pricing Analysis
17.20.2. Market Share Analysis, 2022
17.20.2.1. By Product
17.20.2.2. By Allergen Type
17.20.2.3. By Therapeutics Drug Class
17.20.2.4. By End User
17.21. Israel
17.21.1. Pricing Analysis
17.21.2. Market Share Analysis, 2022
17.21.2.1. By Product
17.21.2.2. By Allergen Type
17.21.2.3. By Therapeutics Drug Class
17.21.2.4. By End User
18. Market Structure Analysis
18.1. Competition Dashboard
18.2. Competition Benchmarking
18.3. Market Share Analysis of Top Players
18.3.1. By Regional
18.3.2. By Product
18.3.3. By Allergen Type
18.3.4. By Therapeutics Drug Class
18.3.5. By End User
19. Competition Analysis
19.1. Competition Deep Dive
19.1.1. bioMerieux SA
19.1.1.1. Overview
19.1.1.2. Product Portfolio
19.1.1.3. Profitability by Market Segments
19.1.1.4. Sales Footprint
19.1.1.5. Strategy Overview
19.1.1.5.1. Marketing Strategy
19.1.2. HOB Biotech Group Corp Ltd
19.1.2.1. Overview
19.1.2.2. Product Portfolio
19.1.2.3. Profitability by Market Segments
19.1.2.4. Sales Footprint
19.1.2.5. Strategy Overview
19.1.2.5.1. Marketing Strategy
19.1.3. Alcon
19.1.3.1. Overview
19.1.3.2. Product Portfolio
19.1.3.3. Profitability by Market Segments
19.1.3.4. Sales Footprint
19.1.3.5. Strategy Overview
19.1.3.5.1. Marketing Strategy
19.1.4. HYCOR Biomedical, Inc.
19.1.4.1. Overview
19.1.4.2. Product Portfolio
19.1.4.3. Profitability by Market Segments
19.1.4.4. Sales Footprint
19.1.4.5. Strategy Overview
19.1.4.5.1. Marketing Strategy
19.1.5. Immunomic Therapeutics
19.1.5.1. Overview
19.1.5.2. Product Portfolio
19.1.5.3. Profitability by Market Segments
19.1.5.4. Sales Footprint
19.1.5.5. Strategy Overview
19.1.5.5.1. Marketing Strategy
19.1.6. Quest Diagnostics Incorporated
19.1.6.1. Overview
19.1.6.2. Product Portfolio
19.1.6.3. Profitability by Market Segments
19.1.6.4. Sales Footprint
19.1.6.5. Strategy Overview
19.1.6.5.1. Marketing Strategy
19.1.7. Omega Diagnostics Group PLC
19.1.7.1. Overview
19.1.7.2. Product Portfolio
19.1.7.3. Profitability by Market Segments
19.1.7.4. Sales Footprint
19.1.7.5. Strategy Overview
19.1.7.5.1. Marketing Strategy
19.1.8. Siemens Healthcare Private Limited
19.1.8.1. Overview
19.1.8.2. Product Portfolio
19.1.8.3. Profitability by Market Segments
19.1.8.4. Sales Footprint
19.1.8.5. Strategy Overview
19.1.8.5.1. Marketing Strategy
19.1.9. Stallergenes Greer
19.1.9.1. Overview
19.1.9.2. Product Portfolio
19.1.9.3. Profitability by Market Segments
19.1.9.4. Sales Footprint
19.1.9.5. Strategy Overview
19.1.9.5.1. Marketing Strategy
19.1.10. Lincoln Diagnostics, Inc.
19.1.10.1. Overview
19.1.10.2. Product Portfolio
19.1.10.3. Profitability by Market Segments
19.1.10.4. Sales Footprint
19.1.10.5. Strategy Overview
19.1.10.5.1. Marketing Strategy
20. Assumptions & Acronyms Used
21. Research Methodology
Explore Healthcare Insights
View Reports
Pollen Allergy Market
